KUALA LUMPUR, May 14 (Bernama) -- Kolmar BNH, a manufacturer of HemoHIM, a health-enhancing functional food, has emerged as a frontrunner in the global Original Development Manufacturing (ODM) market, owing to its pioneering investments in research and development (R&D).
An official from Kolmar BNH said the company remained steadfast in its commitment to R&D, striving to deliver customer-centric services and endeavoured to captivate global clientele by showcasing the technological expertise amassed through years of dedicated innovation.
According to a statement, the cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments.
The company annually allocates over two per cent of its sales revenue to R&D expenditures, bolstering its capabilities by employing more than 30 per cent of its workforce as researchers.
The Health Food Lab, an arm of Kolmar BNH, comprising over 100 researchers with master's and doctoral degrees, is dedicated to pioneering new formulations and functionalities.
Kolmar BNH also maintains relationships with over 300 domestic and international clients, leveraging its R&D prowess that has evolved over an extended period, in which among its key clients include the Korean branch of Haleon, a global healthcare conglomerate.
HemoHIM, distributed by Atomy, which represents a technology-intensive product of Kolmar BNH has penetrated markets in 19 countries, including Australia, the United States, Thailand, Taiwan, Central Asia, and South America.
Meanwhile, ‘HemoHIM G’, tailored for the European market, is another testament to Kolmar BNH's R&D capabilities, whereby this export-oriented product has been meticulously formulated to comply with diverse food regulations across European nations.
Kolmar BNH aims to bolster its global market competitiveness by prioritizing R&D efforts in raw material development, with emphasis on uncovering additional efficacies through in-depth research of Hemohim G.
-- BERNAMA
No comments:
Post a Comment